Health Trials

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

ConditionBiliary Tract Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorEisai Co., Ltd.

About this trial

The primary purpose of this study is to investigate the safety of Tasfygo.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • No Intervention

Treatment groups

60 Participants
are divided into 1 treatment group

Sponsors and collaborators

Eisai Co., Ltd.

Lead sponsor

Source ClinicalTrials.gov